Tag Archives: request

Surveys Show Netflix Winning In U.S., Slow Going In Japan

Consumer surveys show that Netflix ( NFLX ) continues to make subscriber gains in the U.S. but is having a rough time penetrating the market in Japan. RBC Capital Markets surveyed over 1,000 Internet users in the U.S. and over 1,500 in Japan in February about their streaming video usage. The U.S. survey found that 53% of Internet users now use Netflix to watch movies and TV shows, up from 51% in November. By comparison, 46% use Alphabet ’s ( GOOGL ) YouTube and 27% use Amazon.com ( AMZN ) to watch videos. The survey also found near record-high satisfaction levels and near record-low churn. Some 70% of Netflix subscribers say they are “extremely” or “very satisfied” with the service, the second highest level in 18 quarterly surveys and up from 69% in November. Plus, 72% of Netflix subscribers say they are “not at all likely” to cancel, though down from 75% in November. In RBC’s first Netflix survey in Japan, it found that just 1% of respondents use Netflix to watch movies and TV shows. That compares with 39% for YouTube, 13% for Nico Nico & GYAO!, 7% for Amazon and 5% for Hulu. Netflix entered the Japanese market on Sept. 2. RBC analyst Mark Mahaney reiterated his outperform rating on Netflix stock with a price target of 140. Netflix stock was up 3.5% to above 101 in late afternoon trading on the stock market today . Mahaney believes Netflix can climb to 180 million subscribers worldwide by 2020. It ended 2015 with 74.76 million total streaming subscribers, including 44.74 million in the U.S. “We believe that Netflix has achieved a level of sustainable scale, growth, and profitability that isn’t currently reflected in its stock price,” Mahaney said. RELATED: Netflix Growth Potential Underestimated, Analyst Says .

Netflix Retakes Key Level; Apple On Biggest Win Streak Since Sept.

Loading the player… Netflix ( NFLX ) stock has been flying under the radar somewhat, as its performance has lagged over the past few months. But as the market and leading tech stocks continue to recover, the streaming video service is looking to retake a key level in a bullish manner in the stock market today . Netflix on Friday received an upbeat analyst report from RBC Capital Markets, which said that its quarterly survey showed record Netflix viewership. RBC also said half of the respondents felt Netflix had improved its content in the past year. Shares closed up 3.7% in fast turnover, retaking the critical 50-day line and the 100 price level in intraday trade. After hitting a nine-month low around 80 about a month ago, shares have steadily rebounded in quiet trade. Netflix still needs to retake its 200-day line and is trading about 24% below its all-time high reached in early December. Similarly, Apple ( AAPL ) was able to retake its 50-day line and the 100 price level on Tuesday. Apple posted its fourth gain in a row. Apple hasn’t seen consecutive positive action like that since last September. Alphabet, Amazon, Facebook Face Resistance Meanwhile, Google owner Alphabet ( GOOGL ) retook its 50-day line on Tuesday but has since retreated from that level. Alphabet is trading 9% below its February high. Amazon ( AMZN ) looks to be hitting resistance at its 50-day line for a third day in a row. Amazon is trading about 17% below its all-time peak reached in late December. And Facebook ( FB ) is hitting resistance near the 110 price level. Shares broke out past a base with a 110.75 buy point in late January, but the stock quickly turned tail. Facebook is now trading 7% below its high reached during that breakout attempt.

Novo Nordisk Pops As Diabetes Drug Cuts Heart Disease Deaths

Shares of diabetes giant Novo Nordisk ( NVO ) jumped Friday after the company said its drug Victoza reduced heart attacks and strokes. Novo released few details about the results of the study, which it’s saving for the next American Diabetes Association meeting in June. However, it did say that there was a statistically significant reduction in all three of its metrics — heart attack, stroke and death from all cardiovascular causes — among the 9,000 patients taking the diabetes drug over five years, compared to the placebo group. The subjects were all over age 50 and either had cardiovascular disease or multiple risk factors. Novo Nordisk’s stock was up about 8% in afternoon trading on the stock market today , near 57. It’s the highest-rated stock in the low-rated Medical-Ethical Drugs group, with a Composite Rating of 82. The effect of diabetes drugs on cardiovascular health has been the subject of several studies lately, notably from Eli Lilly ( LLY ), whose drug Jardiance reduced deaths from heart failure by 32% in a similar large, long-term study reported last September. On the other hand, Merck ‘s ( MRK ) Januvia showed no effect either good or bad in its outcomes trial reported a few months earlier. A similarly neutral result was reported for an outcomes trial of the Sanofi ( SNY ) drug Elixa, which is noteworthy because Elixa is in the same class as Victoza. Both are glucagon-like peptide-1 (GLP-1) analogs, similar to Bydureon from AstraZeneca ( AZN ) and Lilly’s Trulicity, while Jardiance is an sglt2 inhibitor, in the same class as Invokana from Johnson & Johnson ( JNJ ) and Farxiga from AstraZeneca. Merck’s Januvia belongs to another class, called DPP-4 inhibitors. On a conference call with analysts Friday, Novo’s Chief Scientific Officer Mads Thomsen said that the different results may have come from subtle differences between the drugs, which he thinks extend to Victoza’s planned successor, semaglutide. “It’s not only the question of being a member of the given class of GLP-1 agonist,” said Thomsen. “It’s also a part of the kinetics, dynamics, distribution, half-life, and so on. And as we got semaglutide, we have done rather detailed investigations. . . . There is nothing from the animal pharmacology to negate the notion that semaglutide should do at least as well on cardiovascular performance.”